GLP-1 Drugs should be the first option obesity treatment: European Doctor

The blockbuster weight-loss drugs of Novo Nordisk and Elli Lily should first arrive to treat doctors and to treat its complications, a major European Medical Association on Thursday advised.

Semaglutide, active ingredients in the vegovi and ozmpic of Novo, and Tirzepetide, are sold by lily as zipbound and silence, they are so effective that they can be the first choice in almost all cases, when there is a need to lose adequate weight, where a new guideline of the European Association is published according to a new guideline.

The guideline states that when a low weight loss is required, other drugs can be considered, including liraglutide, an chronic, less effective drug from the same class, a malactraxone-bupropian, and phentymin-topiramate.

Novo shares were 2.2% above 1007 GMT, performing better than European pharmaceuticals peers. The EASO guidelines are non-comprehensive on individual countries.

Semaglutide, tirzeptide and other medications from the class known as GLP-1 agonist are completely changing obesity and its complications, Kothor Dr. Val D’Hebron University Hospital’s Kothor Dr. in Barcelona. Andreya Syudin said in a statement.

Although no treatment algorithm can change the fine clinical decision required for extensive patient care, new guidelines can work to support medical decision making in obesity, he said.

Specific drugs for specific circumstances

The guidelines analyzed the previous clinical testing results, evaluated the effects of drugs on weight loss, their safety profile and their effectiveness in the presence of specific complications.

For patients with too much fatty, or fat, tissue physiological results, tirzeptides should be considered as the first row treatment to address obstructive sleep apnea, and semaglutide, writers for people with osteoarthritis of the knee, prescribed.

For patients with conditions associated with obesity related metabolism and immune relaxation, they recommend semaglutide as the first choice for people with a history of heart disease or stroke, arrowsetide for individuals with non-alcohol fatty liver disease, and either prejudicial or semaglutide for individuals.

The class of drugs was originally developed to treat type 2 diabetes.

While drugs are expensive and economic views are complex, the cost of not treating obesity in the early stages, “thus enabling the progression and progress to the end-of-the-edge damage, we should be weighed evenly in health policy and clinical decision making,” guidelines wrote the authors.

The management of obesity should not be limited to weight loss and its complications, but should also focus on increased mental welfare, physical fitness, social work and overall health and quality of life, he also said.

Most new drugs have not been evaluated to treat individual complications, they accept.

Nevertheless, the authors say, the effects of weight loss are strongly associated with improvement in various complications and for them the ability to positively affect a wide range of disorders such as chronic kidney disease, neurodynative diseases, polycystic ovary syndrome, some cancer and mental health conditions.

“Given the rapid progress in the field of drugs for the treatment of obesity, the EASO has intended to update the latest current treatment algorithm to include the latest available evidence.”

The American College of Lifestyle Medicine, American Society for Nutrition, The Obesity Medicine Association, and Obesity Society jointly advised in June that GLP -1 should be with treatment with nutrition and lifestyle strategies.

“Although GLP1s can produce significant weight loss and related health benefits although many challenges limit its long -term success to individuals and population,” said the advisor, “said the advisor,” said the gastrointestinal side effects, nutrients, insufficiency of nutrients, loss of muscles and bone, loss, high costs, often closing and weight loss, “said the advisor.